Os estudos que marcaram o panorama de câncer de mama no ASCO 2022 estão no PODCAST ONCONEWS, com apresentação de Silvio Bromberg e Daniel Gimenes. Entre os destaques, o primeiro randomizado de Fase 3 a demonstrar benefício clínico e estatisticamente significativo de um agente anti-HER2, o conjugado trastuzumabe-deruxtecana, em pacientes com câncer de mama metastático HER2-low (DESTINY-Breast04); estudo prospectivo que avaliou a omissão de radioterapia após cirurgia conservadora da mama no câncer de mama luminal A de baixo grau (LUMINA); e acompanhamento de 8 anos do estudo randomizado ASTRRA, que avaliou A adição de supressão da função ovariana ao tamoxifeno em mulheres jovens com câncer de mama hormônio-sensível que permanecem no pré-menopausa ou retomam a menstruação após a quimioterapia. Confira.
Referências:
Abstract #LBA3: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. - Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Xiaojia Wang, Binghe Xu, Dhiraj Gambhire, Lotus Yung, Gerold Meinhardt, Yibin Wang, Nadia Harbeck, David A. Cameron - Clinical Trial Registration Number: NCT03734029; Citation: J Clin Oncol 40, 2022 (suppl 17; abstr LBA3); DOI: 10.1200/JCO.2022.40.17_suppl.LBA3
https://meetings.asco.org/abstracts-presentations/209021
Abstract #506: Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial. - Soo Yeon Baek, Woo Chul Noh, Sei-Hyun Ahn, Hyun-Ah Kim, Jai Min Ryu, Seung Il Kim, Eun-Gyeong Lee, Seock-Ah Im, Yongsik Jung, Min Ho Park, Kyong Hwa Park, Su Hwan Kwang, Joon Jeong, Eunhwa Park, Sung Yong Kim, Min Hyuk Lee, Lee Su Kim, Woosung Lim, Seonok Kim, Hee Jeong Kim – Citation: J Clin Oncol 40, 2022 (suppl 16; abstr 506); DOI: 10.1200/JCO.2022.40.16_suppl.506
https://meetings.asco.org/abstracts-presentations/208982
Abstract #LBA501: LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). - Timothy Joseph Whelan, Sally Smith, Torsten O. Nielsen, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Laval Grimard, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Eileen Rakovitch, Valerie Theberge, Anna Marie Mulligan, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Russell Pond, Mark Norman Levine - Clinical Trial Registration Number: NCT01791829; Citation: J Clin Oncol 40, 2022 (suppl 17; abstr LBA501); DOI: 10.1200/JCO.2022.40.17_suppl.LBA501
https://meetings.asco.org/abstracts-presentations/208258
Abstract #503: Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. - Lajos Pusztai, Carsten Denkert, Joyce O'Shaughnessy, Javier Cortes, Rebecca Alexandra Dent, Heather L. McArthur, Sherko Kuemmel, Jonas C. S. Bergh, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Yalin Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid - Clinical Trial Registration Number: NCT03036488; Citation: J Clin Oncol 40, 2022 (suppl 16; abstr 503); DOI: 10.1200/JCO.2022.40.16_suppl.50
https://meetings.asco.org/abstracts-presentations/208272
Abstract #502: Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature. - Pat W. Whitworth, Chirag S. Shah, Frank A. Vicini, Rachel Rabinovitch, Julie A. Margenthaler, Fredrik Warnberg, Brian J. Czerniecki, Michael C. Leo, Sheila Weinmann, Bruce Mann, David J. Dabbs, Jess Savala, Steven C. Shivers, Karuna Mittal, Troy Bremer – Citation: J Clin Oncol 40, 2022 (suppl 16; abstr 502); DOI: 10.1200/JCO.2022.40.16_suppl.502
https://meetings.asco.org/abstracts-presentations/209206
--
